Skip to main content
Access Bio, Inc. logo

Access Bio, Inc. — Investor Relations & Filings

Ticker · 950130 ISIN · KR8840090003 LEI · 335800Q5TV77F4L9Q648 KO Manufacturing
Open in API
Filings indexed 247 across all filing types
Latest filing 2022-02-22 Regulatory Filings
Country IN India
Listing KO 950130

About Access Bio, Inc.

https://accessbio.net/

Access Bio, Inc. is a company dedicated to the prevention and early diagnosis of infectious diseases through the research, development, and manufacturing of in vitro diagnostic solutions. Its portfolio includes rapid diagnostic tests (RDTs), immunochemical diagnostics, biosensors, and molecular diagnostic products. The company is recognized for commercializing high-quality tests to combat significant global health threats, including malaria, COVID-19, HIV, and HPV. With a large-scale manufacturing capacity, Access Bio distributes its products globally, serving as a key partner in global health, particularly in the fight against often-neglected diseases.

Recent filings

Filing Released Lang Actions
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 1% confidence The document is a formal regulatory disclosure regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결) for COVID-19 antigen self-test kits. It details the contract value, counterparty, and duration. Since this is a specific material event disclosure regarding a business contract and does not fit into the other specialized categories like M&A or financial reports, it falls under the general regulatory filing category.
2022-02-22 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. This document details changes in share ownership, including major shareholding notifications and changes in special relationships. It does not fit into categories like 10-K, Earnings Release, or Proxy Solicitation. Given the specific nature of reporting significant shareholding thresholds and changes, it falls under the 'Major Shareholding Notification' category.
2022-01-24 Korean
기타경영사항(자율공시)(20기 정기주주총회 권리주주 확정을 위한 증권예탁증권 기준일 설정 공고)
AGM Information Classification · 1% confidence The document is a short regulatory announcement regarding the setting of a record date for the 20th Annual General Meeting (AGM) to determine shareholder voting rights. It is a formal notice issued by the company to shareholders regarding meeting logistics rather than the meeting materials themselves or a financial report. Given it is a regulatory announcement regarding corporate governance and meeting procedures, it fits best under the RNS (Regulatory Filings) category as a general regulatory announcement.
2021-12-13 Korean
증권발행결과(자율공시)(제5회차 CB)
Capital/Financing Update Classification · 1% confidence The document is a formal announcement regarding the results of a securities issuance (specifically a convertible bond, or CB). It details the issuance amount, payment date, and the nature of the security. This falls under the category of capital and financing updates, specifically related to the issuance of debt/equity instruments.
2021-12-10 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 1% confidence The document is a formal 'Major Matter Report' (주요사항보고서) filed with the Financial Services Commission and the Korea Exchange regarding the issuance of convertible bonds (전환사채권 발행결정). This type of regulatory filing in the Korean market, which details specific capital structure changes, financing terms, and board resolutions, falls under the 'Capital/Financing Update' category.
2021-11-25 Korean
전환가액의조정(제4회차)
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing from Access Bio regarding the adjustment of the conversion price for its 4th series of convertible bonds (CB). It details the change in conversion price, the number of convertible shares, the reason for the adjustment (market price decline), and the calculation methodology. This type of disclosure is a standard capital structure update related to financing instruments, which falls under the 'Capital/Financing Update' category.
2021-11-17 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.